Lexicon Pharmaceuticals (LXRX) Equity Ratio (2023 - 2025)
Lexicon Pharmaceuticals (LXRX) has disclosed Equity Ratio for 6 consecutive years, with 0.58 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio rose 18.86% to 0.58 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.58, a 18.86% increase, with the full-year FY2025 number at 0.58, up 18.86% from a year prior.
- Equity Ratio was 0.58 for Q4 2025 at Lexicon Pharmaceuticals, roughly flat from 0.58 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.69 in Q1 2024 to a low of 0.41 in Q4 2023.
- A 3-year average of 0.55 and a median of 0.56 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: rose 27.95% in 2024, then plummeted 40.3% in 2025.
- Lexicon Pharmaceuticals' Equity Ratio stood at 0.41 in 2023, then rose by 20.51% to 0.49 in 2024, then rose by 18.86% to 0.58 in 2025.
- Per Business Quant, the three most recent readings for LXRX's Equity Ratio are 0.58 (Q4 2025), 0.58 (Q3 2025), and 0.57 (Q2 2025).